Charles Homcy, M.D.
Chairman of the Board; Partner, Third Rock Ventures
Dr. Charles Homcy is a partner at Third Rock Ventures, where he focuses on the formation of companies that discover and develop novel therapeutic approaches. He brings significant experience building and leading successful biotech companies and has played an integral…
View full bio
Nancy Andrews, M.D., Ph.D
DEAN EMERITA, DUKE UNIVERSITY SCHOOL OF MEDICINE
Nancy Andrews, M.D., Ph.D., has extensive experience as a physician, scientist, professor and senior administrator at leading academic institutions and hospitals. Her distinguished career spans more than 30 years, with leadership roles at both Harvard Medical School and the Duke…
View full bio
Brendan Bulik-Sullivan, Ph.D.
Partner, GV
Dr. Brendan Bulik-Sullivan is a partner at GV focusing on life sciences investments. Before GV, Dr. Bulik-Sullivan worked on applied statistics and machine learning research in genetics and biotechnology. Dr. Bulik-Sullivan led machine learning at Gritstone Oncology, where he designed…
View full bio
Jason Coloma, Ph.D.
President, Chief Mazer, MAZE THERAPEUTICS
Dr. Jason Coloma is the CEO of Maze Therapeutics. Prior to his appointment to CEO, he was Maze’s interim chief operating officer and a venture partner at Third Rock Ventures, where he was instrumental in the founding and launch of…
View full bio
Jonathan Lim, M.D.
Founder and managing partner, City Hill Ventures
Jonathan Lim, M.D., is the founder and managing partner at City Hill Ventures. In addition to his role at City Hill, Dr. Lim is a venture partner at ARCH Venture Partners, chairman, chief executive officer and co-founder at Erasca, and…
View full bio
Richard Scheller, Ph.D.
Former head of therapeutics and chief scientific officer, 23andMe
Dr. Richard Scheller is the former head of therapeutics and chief scientific officer of 23andMe. Prior to his role there, he spent 14 years at Genentech where he was executive vice president of research and early development. He served on…
View full bio
Catherine Angell Sohn, Pharm.D.
FORMER SVP, GLAXOSMITHKLINE CONSUMER HEALTHCARE
Catherine Angell Sohn, Pharm.D., is an experienced biopharmaceutical executive with expertise in strategy, strategic product development, business development and commercialization of new medicines. Dr. Sohn currently serves as chairman of the board of BioEclipse Therapeutics and as a director for…
View full bio
Daniel K. Spiegelman
FORMER EVP, CFO, BIOMARIN PHARMACEUTICALS
Daniel K. Spiegelman has served as a chief financial officer in several diversified biotechnology companies spanning 30 years. He was most recently executive vice president and chief financial officer of BioMarin Pharmaceuticals, Inc., a pharmaceutical company focused on development of…
View full bio
Andy Tran
Matrix Capital Management
Andy Tran leads and oversees key private biotechnology investments at Matrix Capital Management, a technology and life sciences investment firm. In addition to serving as Board Director of Maze Therapeutics, he has led investments in and served on the boards…
View full bio
Jeffrey Tong, Ph.D.
Partner, Third Rock Ventures
Dr. Jeffrey Tong is a partner with Third Rock Ventures, where he focuses on drug discovery and development across the firm’s portfolio. He is chairman of Ambys Medicines, and also serves on the board of Nurix Therapeutics. Prior to joining…
View full bio
Sekar Kathiresan, M.D.
Verve Therapeutics, MGH and Broad
Dr. Sek Kathiresan, a physician scientist and a human geneticist, is the CEO of Verve Therapeutics, Professor of Medicine (on leave) at Harvard Medical School, and Institute Member (on leave) at Broad Institute. Sek leverages human genetics to understand the…
View full bio
